He Juan, Chen Yu, Zhao Huakan, Li Yongsheng
Chongqing University Cancer Hospital, School of Medicine, Chongqing University, Chongqing, China.
Department of Medical Oncology, Chongqing University Cancer Hospital, 181 Hanyu Road, Shapingba District, Chongqing, 400030, China.
Mol Med. 2025 Feb 13;31(1):58. doi: 10.1186/s10020-025-01108-6.
Targeted therapy represents a form of cancer treatment that specifically focuses on molecular markers regulating the growth, division, and dissemination of cancer cells. It serves as the cornerstone of precision medicine and is associated with fewer adverse effects compared to conventional chemotherapy, thus enhancing the quality of patient survival. These make targeted therapy as a vital component of contemporary anti-cancer strategies. Although targeted therapy has achieved excellent anti-cancer results, there are still many factors affecting its efficacy. Among the numerous factors affecting anti-cancer treatment, the role of intestinal bacteria and its metabolites are becoming increasingly prominent, particularly in immunotherapy. However, their effects on anticancer targeted therapy have not been systematically reviewed. Herein, we discuss the crosstalk between gut bacteria and anticancer targeted therapies, while also highlighting potential therapeutic strategies and future research directions.
靶向治疗是一种癌症治疗形式，它特别关注调节癌细胞生长、分裂和扩散的分子标志物。它是精准医学的基石，与传统化疗相比，副作用更少，从而提高了患者的生存质量。这些使得靶向治疗成为当代抗癌策略的重要组成部分。尽管靶向治疗已经取得了出色的抗癌效果，但仍有许多因素影响其疗效。在影响抗癌治疗的众多因素中，肠道细菌及其代谢产物的作用日益突出，尤其是在免疫治疗中。然而，它们对抗癌靶向治疗的影响尚未得到系统的综述。在此，我们讨论肠道细菌与抗癌靶向治疗之间的相互作用，同时强调潜在的治疗策略和未来的研究方向。
